Skip to main content

[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis).

REPROCELL will soon have a new, third clinical pipeline: (3.) Tumor-infiltrating lymphocyte infusion therapy (TIL therapy) for cervical cancer.

In June 2023, REPROCELL entered into an agreement with the Department of Obstetrics and Gynecology of Keio University School of Medicine, for the development of a new pipeline for TIL therapy in Advanced Medical Treatment B (Tier II clinical trial of short-term cultured anti-tumor lymphocyte infusion therapy using non-destructive bone marrow pre-treatment and low-dose IL-2). Under this agreement, a joint research and development has been conducted.

REPROCELL will act as the cell processing partner for the clinical trial “Advanced Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy) for Cervical Cancer”, which will be jointly conducted by the Department of Obstetrics and Gynecology, Keio University School of Medicine and the International University of Health and Welfare (see Keio University School of Medicine Press Release).

Upon completion of this clinical trial, REPROCELL will commercialize TIL Therapy as our new clinical pipeline.

About TIL Therapy

Tumor-infiltrating lymphocyte infusion therapy (TIL therapy) is a type of adoptive immunotherapy in which immune cells called tumor-infiltrating lymphocytes (TILs), contained in a patient’s cancer tissue, are harvested and cultured in large numbers outside the body and then the TILs are returned to the patient. TIL therapy has mainly been used for the treatment of advanced malignant melanoma since the 1980s, with most of this treatment being performed in the United States, and its therapeutic effects have been reported. The results of TIL therapy for malignant melanoma show that approximately 70% of patients achieve tumor shrinkage (response rate) and 20% achieve complete disappearance of lesions (complete response). With few exceptions, patients with a complete response do not relapse. 9 cases of recurrent cervical cancer have been reported, and 2 complete responses have been reported, with no recurrence in more than 5 years (J2 Clin Oncol, 2015. 33: 1543-50).

Subscribe to receive updates from REPROCELL